Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is the most common form of irreversible blindness in developed countries. Variants in the factor H gene (CFH, also known as HF1), which encodes a major inhibitor of the alternative complement pathway, are associated with the risk for developing AMD. Here we test the hypothesis that variation in genes encoding other regulatory proteins of the same pathway is associated with AMD. We screened factor B (BF) and complement component 2 (C2) genes, located in the major histocompatibility complex class III region, for genetic variation in two independent cohorts comprising approximately 900 individuals with AMD and approximately 400 matched controls. Haplotype analyses identify a statistically significant common risk haplotype (H1) and two protective haplotypes. The L9H variant of BF and the E318D variant of C2 (H10), as well as a variant in intron 10 of C2 and the R32Q variant of BF (H7), confer a significantly reduced risk of AMD (odds ratio = 0.45 and 0.36, respectively). Combined analysis of the C2 and BF haplotypes and CFH variants shows that variation in the two loci can predict the clinical outcome in 74% of the affected individuals and 56% of the controls. These data expand and refine our understanding of the genetic risk for AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This analysis resulted in the identification of the previously well documented independently associated variants near CFH and C2/CFB8,10,31,32 and of additional independent signals near C3, CETP, LIPC, FRK/COL10A1, IER3/DDR1, RAD51B (Supplementary Table 6).”
From Seven new loci associated with age-related macular degeneration (2013) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Genes in the complement pathway4–11 and a region of chromosome 10 12,13 have now been implicated as the major genetic contributors to disease.”
From Seven new loci associated with age-related macular degeneration (2013) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“These include complement 2 (C2) and/or complement factor B (CFB) (56), complement 3 (C3) (170), and complement factor I (CFI) (44).”
From Unraveling a Multifactorial Late-Onset Disease: From Genetic Susceptibility to Disease Mechanisms for Age-Related Macular Degeneration (2009) · cites this paper as [56]
In the citing paper
“studies have demonstrated that at least one of the two variants associated with AMD—R32Q BF—leads to an impairment in the complement activating function of BF (Gold et al., 2006).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Gold et al., 2006
In the citing paper
“the L9H BF/E318D C2 and R32Q BF/intronic variants of C2 have been shown to be protective for AMD (odds ratio (OR) = 0.45 and 0.36, respectively) by Gold et al.”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Gold et al., 2006
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“Overall type I error rates (α) were retrospectively calculated using a previously described metho”
MethodComplement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Self-citationBird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926
Hageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265
Self-citationDrusen proteome analysis: an approach to the etiology of age-related macular degeneration
Crabb, J. W., Miyagi, M., Gu, X., Shadrach, K., West, K. A., Sakaguchi, H., Kamei, M., Hasan, A., Yan, L., Rayborn, M. E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222551899 · Cited by 1,208
A Fine-Scale Map of Recombination Rates and Hotspots Across the Human Genome
Myers, S., Bottolo, L., Freeman, C., McVean, G., & Donnelly, P. (2005) · Science · doi:10.1126/science.1117196 · Cited by 1,134 · cited 1×
“Fourth, estimated recombination rates from HapMap data indicate regions of high recombination on both sides of the C2/BF locu”
BackgroundA role for local inflammation in the formation of drusen in the aging eye
Anderson, D. H., Mullins, R. F., Hageman, G. S., & Johnson, L. V. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01624-0 · Cited by 1,087
Self-citation
Cited by
Items 201–300 of 1,000
Chiu, K., Chan, T.-F., Wu, A., Leung, I. Y.-P., So, K.-F., & Chang, R. C.-C. (2012) · AGE · doi:10.1007/s11357-011-9260-2 · Cited by 99
“…the activation of complement, Aβ deposition in the extracellular RPE matrix was suggested to be a primary activator of complement cascade in which the components responsible for the alternative activation pathway of the complement system were detected in AMD (Johnson et al. 2002; Gold et al. 2006).”
BackgroundChen, M., Muckersie, E., Robertson, M., Forrester, J. V., & Xu, H. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.09.005 · Cited by 99
C2 and CFB Genes in Age-Related Maculopathy and Joint Action with CFH and LOC387715 Genes
Jakobsdottir, J., Conley, Y. P., Weeks, D. E., Ferrell, R. E., & Gorin, M. B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002199 · Cited by 97
“Although, positive associations in the C2/CFB region have been found and replicated primarily for rare variants [27,60,61], we cannot exclude the possibility that the true causal variant(s) in this region may be common, especially since not all known common SNPs have been typed in C2/CFB studies (Figure S1).”
BackgroundMethodResultInfluentialWang, A. L., Lukas, T. J., Yuan, M., Du, N., Handa, J. T., & Neufeld, A. H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005304 · Cited by 97
“. Similarly, studies of CFB and C2 found variants associated with AMD”
ResultInflammatory Mechanisms of Age-related Macular Degeneration
Knickelbein, J. E., Chan, C.-C., Sen, H. N., Ferris, F. L., & Nussenblatt, R. B. (2015) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000073 · Cited by 97
Molecular genetics of AMD and current animal models
Edwards, A. O., & Malek, G. (2007) · Angiogenesis · doi:10.1007/s10456-007-9064-2 · Cited by 106
“Two variants in nearly complete linkage disequilibrium were protective (L9H in BF and E318D in C2), while two others, also in nearly complete disequilibrium, increased the risk of AMD (R32Q in BF and intronic rs547154 in C2) [35].”
BackgroundInfluentialThe molecular genetic basis of age-related macular degeneration: an overview
Katta, S., Kaur, I., & Chakrabarti, S. (2009) · Journal of Genetics · doi:10.1007/s12041-009-0064-4 · Cited by 121
“Among the variations initially observed in BF, two SNPs (rs4151667 (L9H) and rs641153 (R32Q)) exhibited a higher frequency in the normal controls (Gold et al. 2006).”
BackgroundMethodInfluentialAge-Related Macular Degeneration
Khandhadia, S., Cherry, J., & Lotery, A. J. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0653-2_2 · Cited by 106
Discrimination between host and pathogens by the complement system
Pangburn, M. K., Ferreira, V. P., & Cortes, C. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.11.023 · Cited by 94
“Thus, the genetic complexity of ARMD is much greater than initially thought, but the loss of function and gain of function variants found in multiple complement proteins [79,80] correlating with this disease seem to have straightforward consequences for the progression of this disease.”
BackgroundRelationship between Oxidative Stress, Circadian Rhythms, and AMD
Fanjul‐Moles, M. L., & López-Riquelme, G. O. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7420637 · Cited by 106
“factor B (BF) and complement component 2 (C2) genes are also associated with AMD [155].”
BackgroundAn Eye on Age-Related Macular Degeneration: The Role of MicroRNAs in Disease Pathology
Berber, P., Grassmann, F., Kiel, C., & Weber, B. H. F. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0234-z · Cited by 93
Prediction of Age-related Macular Degeneration in the General Population
Buitendijk, G. H. S., Rochtchina, E., Myers, C., van Duijn, C. M., Lee, K. E., Klein, B. E. K., Meuer, S. M., de Jong, P. T. V. M., Holliday, E. G., Tan, A. G., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.07.053 · Cited by 94
Hollyfield, J. G. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4478 · Cited by 107
Recent advances in the genetics of systemic lupus erythematosus
Thibault Flesher, D. L., Sun, X., Behrens, T. W., Graham, R. R., & Criswell, L. A. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.8 · Cited by 93
Zysset-Burri, D. C., Keller, I., Berger, L. E., Largiadèr, C. R., Wittwer, M., Wolf, S., & Zinkernagel, M. S. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-00141-0 · Cited by 94
Complement Component C3 and Risk of Age-Related Macular Degeneration
Despriet, D. D. G., van Duijn, C. M., Oostra, B. A., Uitterlinden, A. G., Hofman, A., Wright, A. F., ten Brink, J. B., Bakker, A., de Jong, P. T. V. M., Vingerling, J. R., et al. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.09.055 · Cited by 94
Genetics of age-related macular degeneration: current concepts, future directions
DeAngelis, M. M., Silveira, A. C., Carr, E. A., & Kim, I. K. (2011) · Seminars in Ophthalmology · doi:10.3109/08820538.2011.577129 · Cited by 94
Wang, L., Kondo, N., Cano, M., Ebrahimi, K., Yoshida, T., Barnett, B. P., Biswal, S., & Handa, J. T. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.01.015 · Cited by 89
“While the transcription of C3, C5, and CFB was magnified over CSE alone, Nrf2 deficiency did not augment the reduction of complement regulator proteins by CSE.”
BackgroundInfluentialDevelopments in anti-complement therapy; from disease to clinical trial
Harris, C. L., Pouw, R. B., Kavanagh, D., Sun, R., & Ricklin, D. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.06.008 · Cited by 91
The spectrum of phenotypes caused by variants in the CFH gene
Boon, C. J. F., van de Kar, N. C. A. J., Klevering, B. J., KEUNEN, J. E. E., Cremers, F. P. M., Klaver, C. C. W., Hoyng, C. B., Daha, M. R., & den Hollander, A. I. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.02.013 · Cited by 104
Hakobyan, S., Harris, C. L., Tortajada, A., Goicochea de Jorge, E., Garci´a-Layana, A., Ferna´ndez-Robredo, P., Rodri´guez de Co´rdoba, S., & Morgan, B. P. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1523 · Cited by 89
de Lima, L. H. S. G., Schubert, C., Ferrara, D., Merriam, J. E., Imamura, Y., Freund, K. B., Spaide, R. F., Yannuzzi, L. A., & Allikmets, R. L. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.12.018 · Cited by 93
Self-citationTargeting the complement system in systemic lupus erythematosus and other diseases
Barilla-LaBarca, M.-L., Toder, K., & Furie, R. A. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.02.014 · Cited by 91
Bora, N. S., Kaliappan, S., Jha, P., Xu, Q., Sivasankar, B., Harris, C. L., Morgan, B. P., & Bora, P. S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1783 · Cited by 90
Eliminating Complement Factor D Reduces Photoreceptor Susceptibility to Light-Induced Damage
Rohrer, B., Guo, Y., Kunchithapautham, K., & Gilkeson, G. S. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0282 · Cited by 90
Cipriani, V., Leung, H.-T., Plagnol, V., Bunce, C., Khan, J. C., Shahid, H., Moore, A. T., Harding, S. P., Bishop, P. N., Hayward, C., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds225 · Cited by 88
Ng, T. K., Chen, L. J., Liu, D. T. L., Tam, P. O. S., Chan, W. M., Liu, K., Hu, Y. J., Chong, K. K. L., Lau, C. S. L., Chiang, S. W. Y., et al. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1517 · Cited by 94
“, Glu318Asp) also confer increased or decreased susceptibility to AMD.(17) These genes encode regulatory proteins of the alternative complement pathway, supporting the proposition that innate immunity, the complement system, and the inflammatory pathway play major roles in the pathogenesis of AMD.”
BackgroundAssessing Susceptibility to Age-related Macular Degeneration with Proteomic and Genomic Biomarkers
Gu, J., Pauer, G. J. T., Yue, X., Narendra, U., Sturgill, G. M., Bena, J., Gu, X., Peachey, N. S., Salomon, R. G., Hagstrom, S. A., et al. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800453-mcp200 · Cited by 90
Nutritional modulation of age-related macular degeneration
Weikel, K. A., Chiu, C., & Taylor, A. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.03.005 · Cited by 87
“…on complement component 2 and rs4151667 and rs641153 on complement factor B are associated with protective effects with regard to neovascular AMD risk in a metaanalysis of four cohorts, confirming the importance of the complement pathway in AMD pathology (Gold et al., 2006; Hageman et al., 2011).”
BackgroundA computational system to select candidate genes for complex human traits
Gaulton, K. J., Mohlke, K. L., & Vision, T. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm001 · Cited by 103
Charbel Issa, P., Victor Chong, N., & Scholl, H. P. N. (2011) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1568-6 · Cited by 87
“These include genes coding for complement factor B/C2 (CFB) [27–29], C3 [30–32], factor I (FI) [33, 34], and CFH-related proteins 1 and 3 [35, 36].”
BackgroundFritsche, L. G., Fleckenstein, M., Fiebig, B. S., Schmitz-Valckenberg, S., Bindewald-Wittich, A., Keilhauer, C. N., Renner, A. B., Mackensen, F., Mößner, A., Pauleikhoff, D., et al. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-8785 · Cited by 88
Complement Factor H: Spatial and Temporal Expression and Localization in the Eye
Mandal, N. A., & Ayyagari, R. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-1655 · Cited by 85
“The role of inflammation in the pathogenesis of AMD is well documented,(27,28) and the association of AMD with members of the complement system, C-reactive protein (CRP), factor B (BF), complement component 2 (C2), and CFH has been reported.(18,20,22,29,30) Smoking, which increases inflammation, is a potent risk facto…”
BackgroundSeddon, J. M. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23544 · Cited by 91
“These common variants, as well as additional loci identified in complement factor B (CFB) and complement component 2 (C2) are well established in their roles to confer AMD risk.(44,45) The discovery of several complement-related loci lend further support to the theory”
BackgroundYoon, K. D., Yamamoto, K., Ueda, K., Zhou, J., & Sparrow, J. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041309 · Cited by 88
“. This feature is of interest since genetic studies demonstrate that sequence variants in some complement related proteins confer increased risk or protection against age-related macular degeneration (AMD)”
BackgroundModelling the Genetic Risk in Age-Related Macular Degeneration
Grassmann, F., Fritsche, L. G., Keilhauer, C. N., Heid, I. M., & Weber, B. H. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037979 · Cited by 85
Kondo, N., Honda, S., Ishibashi, K., Tsukahara, Y., & Negi, A. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1145 · Cited by 88
Local complement activation in aqueous humor in patients with age-related macular degeneration
Schick, T., Steinhauer, M., Aslanidis, A., Altay, L., Karlstetter, M., Langmann, T., Kirschfink, M., & Fauser, S. (2017) · Eye · doi:10.1038/eye.2016.328 · Cited by 92
Kaur, I., Hussain, A., Hussain, N., Das, T., Pathangay, A., Mathai, A., Hussain, A., Nutheti, R., Nirmalan, P. K., & Chakrabarti, S. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-1430 · Cited by 84
Toll-like receptor polymorphisms and age-related macular degeneration
Edwards, A. O., Chen, D., Fridley, B. L., James, K. M., Wu, Y., Abecasis, G., Swaroop, A., Othman, M., Branham, K., Iyengar, S. K., et al. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1378 · Cited by 84
The Role of Complement Factor H in Age-related Macular Degeneration: A Review
Donoso, L. A., Vrabec, T. R., & Kuivaniemi, H. (2010) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.11.001 · Cited by 92
Reynolds, R., Rosner, B., & Seddon, J. M. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.020 · Cited by 83
Loyet, K. M., DeForge, L. E., Katschke, K. J., Diehl, L., Graham, R. R., Pao, L., Sturgeon, L., Lewin-Koh, S.-C., Hollyfield, J. G., & van Lookeren Campagne, M. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9587 · Cited by 80
Gene–environment interactions in ocular diseases
Saccà, S. C., Bolognesi, C., Battistella, A., Bagnis, A., & Izzotti, A. (2008) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.11.002 · Cited by 90
Progression of Geographic Atrophy and Genotype in Age-Related Macular Degeneration
Klein, M. L., Ferris, F. L., Francis, P. J., Lindblad, A. S., Chew, E. Y., Hamon, S. C., & Ott, J. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.12.012 · Cited by 83
Current therapeutic developments in atrophic age-related macular degeneration
Hanus, J., Zhao, F., & Wang, S. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-306972 · Cited by 90
“The fi rst group of patients received a low-dose regimen of 600 mg weekly for 4 weeks followed by 900 mg for every 2 weeks until week 24.”
MethodChen, Y. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.10 · Cited by 92
Multilocus analysis of age-related macular degeneration
Bergeron-Sawitzke, J., Gold, B., Olsh, A., Schlotterbeck, S., Lemon, K., Visvanathan, K., Allikmets, R., & Dean, M. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2009.23 · Cited by 82
Self-citationFernandes, A. R., Zielińska, A., Sánchez‐López, E., dos Santos, T., García, M. L., Silva, A. M., Karczewski, J., & Souto, E. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052592 · Cited by 91
“The CFH is an essential anti-inflammatory agent; thus, if the activity of the complement is abnormal, the complement cascade activation occurs and, consequently, the inflammatory response in the subretinal tissues [19].”
BackgroundWang, J., Ohno-Matsui, K., Yoshida, T., Kojima, A., Shimada, N., Nakahama, K.-I., Safranova, O., Iwata, N., Saido, T. C., Mochizuki, M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.712 · Cited by 80
Kam, J. H., Lenassi, E., Malik, T. H., Pickering, M. C., & Jeffery, G. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.04.008 · Cited by 87
Hong, T., Tan, A. G., Mitchell, P. L. R., & Wang, J. J. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.08.007 · Cited by 85
Sobrin, L., Ripke, S., Yu, Y., Fagerness, J. A., Bhangale, T., Tan, P. L., Souied, E. H., Buitendijk, G. H. S., Merriam, J. E., Richardson, A. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.014 · Cited by 88
Self-citationde Amorim Garcia Filho, C. A., Yehoshua, Z., Gregori, G., Nunes, R. P., Penha, F. M., Moshfeghi, A. A., Zhang, K., Feuer, W., & Rosenfeld, P. J. (2014) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/23258160-20131217-01 · Cited by 79
Genetics of Immunological and Inflammatory Components in Age-related Macular Degeneration
Tuo, J., Grob, S., Zhang, K., & Chan, C.-C. (2012) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2011.628432 · Cited by 80
Complement system and age-related macular degeneration: drugs and challenges
Wu, J., & Sun, X. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s206355 · Cited by 81
“Furthermore, genetic studies have revealed that haplotype (H1) variant of FB is a risk factor for AMD, suggesting the relationship between FB and AMD.(78) Therefore, anti-CFB might work.”
Macrophages in neovascular age-related macular degeneration: friends or foes?
Skeie, J. M., & Mullins, R. F. (2009) · Eye · doi:10.1038/eye.2008.206 · Cited by 78
Mandal, M. N. A., Vasireddy, V., Reddy, G. B., Wang, X., Moroi, S. E., Pattnaik, B. R., Hughes, B. A., Heckenlively, J. R., Hitchcock, P. F., Jablonski, M. M., et al. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.06-0312 · Cited by 84
“Members of the complement system, complement factor H (CFH), C-reactive protein (CRP), factor B and complement component 2 are associated with age-related macular degeneration.(10,12,48) Late-onset retinal degeneration associated with a missense mutation in the CTRP5 gene shares several phenotypic features with AMD, i…”
BackgroundYu, T., Liao, J., Zhang, Y., Zhou, J., Zhang, H., & Mao, M. (2010) · PubMed Central · Cited by 91
AMD and the alternative complement pathway: genetics and functional implications
Tan, P. L., Bowes Rickman, C., & Katsanis, N. (2016) · Human Genomics · doi:10.1186/s40246-016-0079-x · Cited by 79
“37 Common Signal peptide Affects secretion of CFB Decrease formation of C3 convertase; reduced AP [12]”
BackgroundSobrin, L., Reynolds, R., Yu, Y., Fagerness, J., Leveziel, N., Bernstein, P. S., Souied, E. H., Daly, M. J., & Seddon, J. M. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.08.015 · Cited by 78
Complement in age-related macular degeneration: a focus on function
Bradley, D., Zipfel, P. F., & Hughes, A. E. (2011) · Eye · doi:10.1038/eye.2011.37 · Cited by 85
A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy
Huang, L., Zhang, H., Cheng, C., Wen, F., Tam, P. O. S., Zhao, P., Chen, H., Li, Z., Chen, L., Tai, Z., et al. (2016) · Nature Genetics · doi:10.1038/ng.3546 · Cited by 80
Risk Assessment Model for Development of Advanced Age-Related Macular Degeneration
Klein, M. L., Francis, P. J., Ferris, F. L., Hamon, S., & Clemons, T. E. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.216 · Cited by 85
Collier, R. J., Wang, Y., Smith, S. S., Martin, E., Ornberg, R., Rhoades, K., & Romano, C. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6418 · Cited by 78
Complement activation levels are related to disease stage in AMD
Heesterbeek, T. J., Lechanteur, Y. T. E., Lorés-Motta, L., Schick, T., Daha, M. R., Altay, L., Liakopoulos, S., Smailhodzic, D., den Hollander, A. I., Hoyng, C. B., et al. (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.61.3.18 · Cited by 76
Francis, P. J., Schultz, D. W., Hamon, S., Ott, J., Weleber, R. G., & Klein, M. L. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001197 · Cited by 74
“Other genes have been implicated in AMD development, including complement component 2 (CF2) and factor B (BF),”
BackgroundC-Reactive Protein and the Incidence of Macular Degeneration: Pooled Analysis of 5 Cohorts
Mitta, V. P., Christen, W. G., Glynn, R. J., Semba, R. D., Ridker, P. M., Rimm, E. B., Hankinson, S. E., & Schaumberg, D. A. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.2303 · Cited by 74
Age-related macular degeneration: Complement in action
van Lookeren Campagne, M., Strauss, E. C., & Yaspan, B. L. (2016) · Immunobiology · doi:10.1016/j.imbio.2015.11.007 · Cited by 76
Ross, R. J., Bojanowski, C. M., Wang, J. J., Chew, E. Y., Rochtchina, E., Ferris, F. L., Mitchell, P., Chan, C.-C., & Tuo, J. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0999 · Cited by 75
Friedrich, U., Myers, C. A., Fritsche, L. G., Milenkovic, A., Wolf, A., Corbo, J. C., & Weber, B. H. F. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr020 · Cited by 80
Yang, S., Li, T., Jia, H., Gao, M., Li, Y., Wan, X., Huang, Z., Li, M., Zhai, Y., Li, X., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj2177 · Cited by 78
Richards, A., Kavanagh, D., & Atkinson, J. P. (2007) · Advances in immunology · doi:10.1016/s0065-2776(07)96004-6 · Cited by 79
Lenis, T. L., Sarfare, S., Jiang, Z., Lloyd, M. B., Bok, D., & Radu, R. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620299114 · Cited by 72
Plasma Protein Pentosidine and Carboxymethyllysine, Biomarkers for Age-related Macular Degeneration
Ni, J., Yuan, X., Gu, J., Yue, X., Gu, X., Nagaraj, R. H., & Crabb, J. W. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900127-mcp200 · Cited by 72
Triebwasser, M. P., Roberson, E. D. O., Yu, Y., Schramm, E. C., Wagner, E. K., Raychaudhuri, S., Seddon, J. M., & Atkinson, J. P. (2015) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-17432 · Cited by 70
Implications of genetic variation in the complement system in age-related macular degeneration
de Jong, S., Gagliardi, G., Garanto, A., de Breuk, A., Lechanteur, Y. T. E., Katti, S., van den Heuvel, L. P., Volokhina, E. B., & den Hollander, A. I. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100952 · Cited by 71
“Leu9His variant (Gold et al., 2006); the CFB variant has been”
BackgroundKunchithapautham, K., & Rohrer, B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.214593 · Cited by 71
Ocular Vascular Diseases: From Retinal Immune Privilege to Inflammation
Wang, X., Wang, T., Lam, E., Álvarez, D., & Sun, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512090 · Cited by 76
Smailhodzic, D., Fleckenstein, M., Theelen, T., Boon, C. J. F., van Huet, R. A. C., van de Ven, J. P. H., den Hollander, A. I., Schmitz-Valckenberg, S., Hoyng, C. B., Weber, B. H. F., et al. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7926 · Cited by 76
Cuticular drusen: Stars in the sky
Boon, C. J. F., van de Ven, J. P. H., Hoyng, C. B., den Hollander, A. I., & Klevering, B. J. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.08.003 · Cited by 75
The role of complement in ocular pathology
Bora, N. S., Jha, P., & Bora, P. S. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0110-y · Cited by 67
“In a recent study, Gold et al. reported that complement components— factor B (CFB) and complement component 2 (C2)—are also associated with AMD [ 84 ].”
BackgroundProgress in defining the molecular biology of age related macular degeneration
Lotery, A. J., & Trump, D. (2007) · Human Genetics · doi:10.1007/s00439-007-0406-3 · Cited by 75
“Once it had been shown that abnormal complement regulation was likely to be important in susceptibility to AMD further investigation of other regulators of the alternative complement pathway revealed an association between AMD and complement factors B and C2 (Gold et al. 2006).”
BackgroundComplement Component 3 (C3) Haplotypes and Risk of Advanced Age-Related Macular Degeneration
Park, K. H., Fridley, B. L., Ryu, E., Tosakulwong, N., & Edwards, A. O. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3231 · Cited by 69
Liu, X., Zhao, P., Tang, S., Lü, F., Hu, J., Lei, C., Yang, X. Q., Lin, Y., Ma, S., Yang, J., et al. (2010) · Retina · doi:10.1097/iae.0b013e3181cea676 · Cited by 73
Complement activation as a biomarker for Alzheimer's disease
Aiyaz, M., Lupton, M. K., Proitsi, P., Powell, J. F., & Lovestone, S. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.07.023 · Cited by 77
Machalińska, A., Kawa, M. P., Marlicz, W. M., & Machaliński, B. (2011) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02295.x · Cited by 77
“Sequence variants of complement components, for example C3, C2, factor B, and H, have been shown to predispose to AMD (Gold et al. 2006; Yates et al. 2007).”
BackgroundGenetics and molecular pathology of Stargardt-like macular degeneration
Vasireddy, V., Wong, P., & Ayyagari, R. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.01.001 · Cited by 68
“In addition, a number of gene variants associated with AMD, such as specific complement factor-H and B (CFH and CFB) alleles among others, have been identified that modify the risk for developing AMD (Edwards et al., 2005; Haines et al., 2005; Klein et al., 2005; Gold et al., 2006; Yates et al., 2007; Swaroop et al.,…”
BackgroundCruz‐Guilloty, F., Saeed, A. M., Duffort, S., Cano, M., Ebrahimi, K. B., Ballmick, A., Tan, Y., Wang, H., Laird, J. M., Salomon, R. G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088201 · Cited by 75
Zipfel, P. F., Hallström, T., Hammerschmidt, S., & Skerka, C. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.11.015 · Cited by 68
miRNAs as potential therapeutic targets for age-related macular degeneration
Wang, S., Koster, K. M., He, Y., & Zhou, Q. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.11.176 · Cited by 67
Genetics and genetic testing for age-related macular degeneration
Warwick, A., & Lotery, A. (2018) · Eye · doi:10.1038/eye.2017.245 · Cited by 67
Shiose, S., Chen, Y., Okano, K., Roy, S., Kohno, H., Tang, J., Pearlman, E., Maeda, T., Palczewski, K., & Maeda, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228551 · Cited by 65
Age-Related Macular Degeneration: Clinical Findings, Histopathology and Imaging Techniques
Zarbin, M. A., Casaroli-Marano, R. P., & Rosenfeld, P. J. (2014) · Developments in ophthalmology · doi:10.1159/000358536 · Cited by 82
Lauer, N., Mihlan, M., Hartmann, A., Schlötzer-Schrehardt, U. M., Keilhauer, C. N., Scholl, H. P. N., Issa, P. C., Holz, F. G., Weber, B. H. F., Skerka, C., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002488 · Cited by 75
“Genetic polymorphisms in genes coding for Factor H (7–9), Factor B, C2 (10), C3 (11), as well as a 84-kbp chromosomal deletion that results in the absence of the complement regulator CFHR1 and also of CFHR3 significantly influence AMD pathogenesis (12–14).”
BackgroundKawa, M. P., Machalińska, A., Rogińska, D., & Machaliński, B. (2014) · Journal of Immunology Research · doi:10.1155/2014/483960 · Cited by 73
“3 rs547154 IVS10 (intron 10 of C2) P [34, 39, 41, 42]”
BackgroundCoughlin, B., Schnabolk, G., Joseph, K., Raikwar, H., Kunchithapautham, K., Johnson, K., Moore, K., Wang, Y., & Rohrer, B. (2016) · Scientific Reports · doi:10.1038/srep23794 · Cited by 65
Mechanism of Inflammation in Age-Related Macular Degeneration: An Up-to-Date on Genetic Landmarks
Parmeggiani, F., Sorrentino, F. S., Romano, M. R., Costagliola, C., Semeraro, F., Incorvaia, C., D’Angelo, S., Perri, P., Nadai, K. D., Roversi, E. B., et al. (2013) · Mediators of Inflammation · doi:10.1155/2013/435607 · Cited by 67
“95 G-to-A (H7 haplotype) confer a significantly reduced risk forAMD[145].”
BackgroundMethodChi, Z.-L., Yoshida, T., Lambris, J. D., & Iwata, T. (2010) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-5635-4_9 · Cited by 64
“Another recent study reported that a haplotype association of tandemly located complement 2 and factor B (Gold et al. 2006) was protective and C3 (Yates et al.”
Savastano, M. C., Minnella, A. M., Tamburrino, A., Giovinco, G., Ventre, S., & Falsini, B. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-12172 · Cited by 65
Metadata
- Authors
- The AMD Genetics Clinical Study Group, Gold, B., Merriam, J. E., Zernant, J., Hancox, L. S., Taiber, A. J., Gehrs, K., Cramer, K., Neel, J., Bergeron, J., Barile, G. R., Smith, R. T., Hageman, G. S., Dean, M., & Allikmets, R.
- Affiliations
- National Cancer Institute (US)
- Columbia University (US)
- University of Iowa (US)
- Science Applications International Corporation (United States) (US)
- Corresponding author
- Dean, Michael
- Allikmets, Rando
- ORCID
- Venue
- Nature Genetics
- Published
- 2006-03-05
- Volume
- 38
- Issue
- 4
- Pages
- 458-462
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC2921703
- OpenAlex
- W1997288094
- Cited by
- 1,075
- References
- 31
- Citations by year
- 2026: 17 · 2025: 17 · 2024: 18 · 2023: 17 · 2022: 27 · 2021: 40 · 2020: 33 · 2019: 28 · 2018: 27 · 2017: 31 · 2016: 47 · 2015: 65 · 2014: 74 · 2013: 69 · 2012: 90
- FWCI
- 85.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Eye Institute (EY11515, R01EY013435, EY-13435, R01EY015520, R01EY011515)
- National Cancer Institute (N01-CO-124000)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- age-related macular degeneration, factor B, alternative complement pathway, genetic risk variants, haplotypes, complement factor H, MHC class III, genetic susceptibility
- MeSH terms
- Aged, Aged, 80 and over, Aging, Chromatography, High Pressure Liquid, Complement C2, Haplotypes, Humans, Immunohistochemistry, Macular Degeneration, Molecular Sequence Data, Complement Factor B, Cohort Studies, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.